Compare SLE & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLE | NRXP |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.4M | 153.2M |
| IPO Year | 2019 | 2017 |
| Metric | SLE | NRXP |
|---|---|---|
| Price | $3.89 | $3.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $60.00 | $38.25 |
| AVG Volume (30 Days) | ★ 1.9M | 991.4K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.70 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,064,000.00 | $1,225,000.00 |
| Revenue This Year | $24.86 | $2,547.84 |
| Revenue Next Year | $49.77 | $1,591.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 90.41 | N/A |
| 52 Week Low | $0.48 | $1.65 |
| 52 Week High | $11.43 | $5.06 |
| Indicator | SLE | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 49.57 | 47.48 |
| Support Level | $2.89 | $3.09 |
| Resistance Level | $4.89 | $3.62 |
| Average True Range (ATR) | 0.75 | 0.21 |
| MACD | -0.06 | 0.02 |
| Stochastic Oscillator | 17.10 | 58.35 |
Super League Enterprise Inc connects brands with the gaming population of around 3.5 billion through advertising and branded content programs across gaming and digital media platforms. The Company generates revenue by delivering these programs through proprietary interactive formats, creator content, immersive experiences, data-driven insights, and strategic campaign services designed to improve marketing performance. By translating player behavior into actionable intelligence, Super League serves as a trusted partner helping brands reach and influence consumers who play video games. With a deep understanding of this engaged yet under-monetized audience, it is positioned to capture an increasing share of brand advertising spend as the market evolves.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.